Atrophic Vaginitis - Epidemiology Forecast - 2032

DelveInsight’s "Atrophic vaginitis - Epidemiology Forecast—2032" report delivers an in-depth understanding of the Atrophic vaginitis, historical and forecasted epidemiology as well as the Atrophic vaginitis trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019-2032

Atrophic vaginitis Understanding

The DelveInsight’s Atrophic vaginitis epidemiology report gives a thorough understanding of Atrophic vaginitis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Atrophic vaginitis, also called vaginal atrophy, is a condition where the lining of the vagina gets drier and thinner. This results in itching, burning, and pain during sex, among other symptoms. The condition also includes urinary tract problems such as urinary tract infections (UTIs) and frequent urination. Vaginal refers to the vagina, while atrophy means a wasting away or diminution. And the term vaginal atrophy has been replaced with the newer term, genitourinary syndrome of menopause (GSM). This new term helps describe not just the vaginal but also the urinary symptoms that can be accompanied by the effects of low estrogen.

The initial symptom is often a lack of lubrication during intercourse. Eventually, persistent vaginal dryness may occur. Thinning of the epithelial lining may also cause pruritus, soreness, and stinging pain in the vaginal and vulvar area, which, in turn, may further contribute to dyspareunia. Vaginal spotting, due to small tears in the vaginal epithelium, may also occur. Women with atrophic vaginitis may report a thin yellow or grey watery discharge secondary to the rise in pH that accompanies atrophic vaginitis.

Diagnosis

Diagnosis of vaginal atrophy based on the symptoms and a pelvic exam to look at how the vagina appears. It will help to know that patients are in menopause. Classic signs of atrophy during a pelvic exam include a shortened or narrowed vagina, dryness, redness, swelling, loss of stretch in the skin, whitish discoloration to the vagina, urethral lesions, and minor cuts (lacerations) near the vaginal opening. And occasionally, laboratory tests are required to differentiate vaginal atrophy from other conditions, such as Pap test, urine sample, ultrasound, serum hormone testing, vaginal pH, and microscopy.

Atrophic vaginitis Epidemiology

The epidemiology section provides insights about the historical and current Atrophic vaginitis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Atrophic vaginitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

In the year 2021, the total diagnosed cases of Atrophic vaginitis was 22.48 million cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

The disease epidemiology covered in the report provides historical as well as forecasted Atrophic vaginitis epidemiology [segmented as Total Prevalent Cases of Atrophic vaginitis, Total Diagnosed Cases of Atrophic vaginitis, Total Atrophic Vaginitis cases by severity and Total Patients taking Prescription treatment] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Atrophic vaginitis Epidemiology

The epidemiology segment also provides the Atrophic vaginitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

KOL- Views

To keep up with the current Atrophic vaginitis patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Atrophic vaginitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report
The report covers the descriptive overview of Atrophic vaginitis, explaining their causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of Atrophic vaginitis.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report provides the segmentation of the disease epidemiology for 7MM by total Prevalent Cases of Atrophic vaginitis, total Diagnosed Cases of Atrophic vaginitis, total Atrophic Vaginitis cases by severity and Total Patients taking Prescription treatment.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Atrophic vaginitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atrophic vaginitis

Atrophic vaginitis Report Key Strengths
11 Years Forecast
7MM Coverage
Atrophic vaginitis Epidemiology Segmentation

Key Questions

Epidemiology Insights:
What are the disease risk, burden, and regional/ethnic differences of Atrophic vaginitis?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What is the historical Atrophic vaginitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Atrophic vaginitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
Where will be the growth opportunities in the 7MM concerning the patient population about Atrophic vaginitis?
Out of all 7MM countries, which country would have the highest prevalent population of Atrophic vaginitis during the forecast period (2019-2032)?
At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Atrophic vaginitis Disease market
To understand the future market competition in the Atrophic vaginitis Disease market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Atrophic vaginitis Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for the Atrophic vaginitis Disease market
To understand the future market competition in the Atrophic vaginitis Disease market